Publicité
Publicité

CAI

C

Caris Life Sciences, Inc. Common Stock

28.80
USD
Sponsorisé
+0.42
+1.48%
07 janv., 16:00 UTC -5
Fermé
exchange

Après-marché

28.93

+0.13
+0.44%

CAI Rapports sur les bénéfices

Ratio de surprise positive

CAI a dépassé 1 des 2 dernières estimations.

50%

Prochain rapport

Date du prochain rapport
--
Estimate for Q-- -- (Revenue/ EPS)
--
/
--
Variation implicite de Q3 25 (Revenue/ EPS)
--
/
--
Variation implicite de Q-- -1 (Revenue/ EPS)
--
/
--

Caris Life Sciences, Inc. Common Stock earnings per share and revenue

On 05 nov. 2025, CAI reported earnings of 0.08 USD per share (EPS) for Q3 25, beating the estimate of -0.21 USD, resulting in a 138.66% surprise. Revenue reached 216.83 million, compared to an expected 171.86 million, with a 26.17% difference. The market reacted with a -15.75% price change (close before vs. close after earnings).
Looking ahead to -- --, -- analystes forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
FAQ
For Q3 2025, Caris Life Sciences, Inc. Common Stock reported EPS of $0.08, beating estimates by 138.66%, and revenue of $216.83M, 26.17% above expectations.
The stock price moved down -15.75%, changed from $29.21 before the earnings release to $24.61 the day after.
The next earning report is scheduled for --.
Based on -- analystes, Caris Life Sciences, Inc. Common Stock is expected to report EPS of -- and revenue of -- for Q-- --.
Chèque FXEmpire's Earnings Calendar for today's list of reporting companies.
Publicité